---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-24-000031"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:14:13.128380+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma Q1 GAAP net loss $14.6M, non-GAAP EPS $2.68; affirms FY24 revenue guidance $4.0-4.2B

## Summary
- Total revenues $902M (+1% YoY); GAAP net loss $14.6M ($0.23 loss/diluted) vs net income $69.4M ($1.04/diluted) in 1Q23.
- Non-GAAP adjusted net income $182.2M ($2.68 EPS) down from $285.3M ($3.95 EPS); cost increases in SG&A and R&D.
- Key growth drivers: Xywav +14%, Epidiolex +5%, Rylaze +20% YoY; Xyrem fell 64% to $64.2M.
- Oncology revenues +13% to $257.5M; zanidatamab BLA for 2L BTC submitted; Phase 2b suvecaltamide data expected late 1H24.
- FY24 guidance affirmed: total revenue $4.0-4.2B, non-GAAP gross margin ~93%, non-GAAP EPS $18.15-19.35.

## SEC filing metadata
- accession: 0001232524-24-000031
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252424000031/0001232524-24-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252424000031/jazz-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-24-000031
- JSON: https://secwatch.observer/filing/0001232524-24-000031.json
- Plain text: https://secwatch.observer/filing/0001232524-24-000031.txt

## Key facts
- Earnings Releases
  Jazz Pharmaceuticals plc updated its first quarter of 2024 guidance (reaffirmed).
  - Period: first quarter of 2024
  - Guidance: reaffirmed
  - Result: reported results
  source text: Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2024 and affirmed guidance for 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000123252424000031/0001232524-24-000031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.